Aaron N Chang

20200383963, Dec 10, 2020

Jan 21, 2020

16/748217

- Cambridge MA, US
Luis Gustavo Alejandro ROJAS SOTO - Cambridge MA, US
Owen Brendan WALLACE - Brookline MA, US
Lucienne V. RONCO - Wellesley MA, US
Ning SHEN - Cambridge MA, US
Alan Scott ROBERTSON - Cambridge MA, US
Aaron Nakwon CHANG - Lexington MA, US

A61K 31/4418
A61K 31/4439
A61K 31/519
A61K 31/437
A61K 31/496
A61K 31/5377
A61K 31/53
A61K 31/416
A61K 31/454
A61K 31/513
A61K 31/506
A61P 21/00
C12Q 1/6883
C12Q 1/6827
C12Q 1/686

The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, orZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.

20200332291, Oct 22, 2020

Oct 5, 2018

16/753664

- Cambridge MA, US
Luis Gustavo Alejandro ROJAS SOTO - Cambridge MA, US
Owen Brendan WALLACE - Brookline MA, US
Lucienne V. RONCO - Wellesley MA, US
Ning SHEN - Cambridge MA, US
Alan Scott ROBERTSON - Cambridge MA, US
Aaron Nakwon CHANG - Lexington MA, US

C12N 15/113
A61K 31/4418
A61K 31/4439
A61K 31/519
A61K 31/506
A61P 21/00

The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).

20150221205, Aug 6, 2015

Nov 7, 2014

14/536293

Aaron CHANG - Grand Prairie TX, US
Melinda CHEN - Lutherville MD, US
Piyush PODDAR - Cranbury NJ, US
Rohil MALPANI - Kolkata, IN
Peter MALAMAS - Jamison PA, US
Sandya SUBRAMANIAN - Grand Rapids MI, US
Joon EOH - College Station TX, US
Kevin GEORGE - Santa Fe Springs CA, US
Todd J. COHEN - Port Washington NY, US

G08B 21/18
G08B 21/02

A method and system for improving the effectiveness of cardioversion and defibrillation through the ability to reduce transthoracic impedance. A method and system of decreasing transthoracic impedance that allows standardized pressure to be applied directly over desired defibrillator patches. This system reduces transthoracic impedance by increasing effective pressure on desired patches through use of a manual depressor device which incorporates a deformable patient body interface and mechanical and or electronic mechanisms to provide qualitative and or quantitative feedback on the force being applied to said patches. By depressing the device over desired external adhesive electrode patches until an audio and or visual signal indicates sufficient applied pressure, increased patch to skin contact is achieved to decrease the effective transthoracic impedance of a patient upon delivery of a defibrillation shock.